Skip to main content
Erschienen in: Journal of Hematopathology 3/2019

11.07.2019 | Original Article

Association between serum levels of hepcidin and ferritin in patients with thalassemia major and intermedia, the role of iron chelator

verfasst von: Seyed Kamal Eshagh Hossaini, Mohammad reza Haeri

Erschienen in: Journal of Hematopathology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Patients with beta-thalassemia suffer from iron overload, and hepcidin, as the main regulator of iron hemostasis, can indicate iron overload better than serum ferritin, but changes in serum hepcidin levels are affected by the type of thalassemia (major or intermediate) and by type of treatments. The present study aimed to determine the correlation between serum levels of hepcidin and ferritin in patients with thalassemia major and intermedia under chelation therapy. This cohort study investigated 143 patients with thalassemia (122 patients with thalassemia major and 21 patients with and thalassemia intermedia) who referred to Thalassemia Center of Qom University of Medical Sciences, Qom, Iran. The serum level of ferritin was measured twice in all patients: in the beginning and after taking iron chelator by ECL method. Hepcidin was assayed at the end of the study by ELISA methods. Demographic data and clinical history of the patients (type of disease, type of drugs used, and blood transfusion history) were completely recorded. The mean serum level of hepcidin in the TM group (2249.62 ± 1547.37 ng/ml) was greater than the TI group (1482.43 ± 1314.26 ng/ml) (p = 0.007). However, there was no meaningful difference in serum ferritin level between the two groups (2997.74 ± 2545.66 vs. 2670.62 ± 2670.04 ng/ml, p > 0.05). Serum ferritin and hepcidin levels were not correlated both in TM or TI patients (p > 0.05). However, evaluating the trend of changes in serum levels of ferritin with hepcidin showed a significant association. High serum levels of ferritin indicated high iron overload in both groups, TM and TI, which decreased after treatment with chelators. The higher hepcidin levels in TM patients in comparison to TI patients could reflect the higher iron overload in these patients. However, further cellular studies are needed to evaluate the accuracy of these tests in the assessment of iron overload.
Literatur
2.
Zurück zum Zitat Muncie HL Jr, Campbell J (2009) Alpha and beta thalassemia. Am Fam Physician 80(4):339–344PubMed Muncie HL Jr, Campbell J (2009) Alpha and beta thalassemia. Am Fam Physician 80(4):339–344PubMed
3.
Zurück zum Zitat Weatherall DJ (2008) Hemoglobinopathies worldwide: present and future. Curr Mol Med 8(7):592–599CrossRefPubMed Weatherall DJ (2008) Hemoglobinopathies worldwide: present and future. Curr Mol Med 8(7):592–599CrossRefPubMed
5.
Zurück zum Zitat Fallah MS, Samavat A, Zeinali S (2009) Iranian national program for the prevention of thalassemia and prenatal diagnosis: mandatory premarital screening and legal medical abortion. Prenat Diagn 29(13):1285–1286CrossRefPubMed Fallah MS, Samavat A, Zeinali S (2009) Iranian national program for the prevention of thalassemia and prenatal diagnosis: mandatory premarital screening and legal medical abortion. Prenat Diagn 29(13):1285–1286CrossRefPubMed
6.
Zurück zum Zitat Saffi M, Howard N (2015) Exploring the effectiveness of mandatory premarital screening and genetic counselling programmes for beta-thalassaemia in the Middle East: a scoping review. Public Health Genomics 18(4):193–203CrossRefPubMed Saffi M, Howard N (2015) Exploring the effectiveness of mandatory premarital screening and genetic counselling programmes for beta-thalassaemia in the Middle East: a scoping review. Public Health Genomics 18(4):193–203CrossRefPubMed
8.
Zurück zum Zitat Ozment CP, Turi JL (2009) Iron overload following red blood cell transfusion and its impact on disease severity. Biochim Biophys Acta 1790(7):694–701CrossRefPubMed Ozment CP, Turi JL (2009) Iron overload following red blood cell transfusion and its impact on disease severity. Biochim Biophys Acta 1790(7):694–701CrossRefPubMed
9.
Zurück zum Zitat Ashayeri N, Sadeghi E, Sadeghi S, Eshghi P, Alavi S (2016) Efficacy of Deferasirox (Exjade®) versus Osveral® in treatment of Iron overload in patients with Beta-thalassemia major in Iran; a non-randomized controlled trial. Iran J Blood Cancer 8(4):103–107 Ashayeri N, Sadeghi E, Sadeghi S, Eshghi P, Alavi S (2016) Efficacy of Deferasirox (Exjade®) versus Osveral® in treatment of Iron overload in patients with Beta-thalassemia major in Iran; a non-randomized controlled trial. Iran J Blood Cancer 8(4):103–107
10.
Zurück zum Zitat Taher AT, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Ros J, Zhang Y, Habr D, Cappellini MD (2012) Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood. 120(5):970–977CrossRefPubMed Taher AT, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Ros J, Zhang Y, Habr D, Cappellini MD (2012) Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood. 120(5):970–977CrossRefPubMed
11.
Zurück zum Zitat Gardenghi S, Marongiu MF, Ramos P, Guy E, Breda L, Chadburn A, Liu Y, Amariglio N, Rechavi G, Rachmilewitz EA, Breuer W, Cabantchik ZI, Wrighting DM, Andrews NC, de Sousa M, Giardina PJ, Grady RW, Rivella S (2007) Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood. 109(11):5027–5035CrossRefPubMedPubMedCentral Gardenghi S, Marongiu MF, Ramos P, Guy E, Breda L, Chadburn A, Liu Y, Amariglio N, Rechavi G, Rachmilewitz EA, Breuer W, Cabantchik ZI, Wrighting DM, Andrews NC, de Sousa M, Giardina PJ, Grady RW, Rivella S (2007) Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood. 109(11):5027–5035CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Nemeth E, Ganz T (2006) Regulation of iron metabolism by hepcidin. Annu Rev Nutr 26:323–342CrossRefPubMed Nemeth E, Ganz T (2006) Regulation of iron metabolism by hepcidin. Annu Rev Nutr 26:323–342CrossRefPubMed
13.
Zurück zum Zitat De Franceschi L, Daraio F, Filippini A, Carturan S, Muchitsch EM, Roetto A et al (2006) Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia. Haematologica. 91(10):1336–1342PubMed De Franceschi L, Daraio F, Filippini A, Carturan S, Muchitsch EM, Roetto A et al (2006) Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia. Haematologica. 91(10):1336–1342PubMed
14.
Zurück zum Zitat Kaddah AM, Abdel-Salam A, Farhan MS, Ragab R (2017) Serum hepcidin as a diagnostic marker of severe iron overload in beta-thalassemia major. Indian J Pediatr 84(10):745–750CrossRefPubMed Kaddah AM, Abdel-Salam A, Farhan MS, Ragab R (2017) Serum hepcidin as a diagnostic marker of severe iron overload in beta-thalassemia major. Indian J Pediatr 84(10):745–750CrossRefPubMed
15.
Zurück zum Zitat Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E (2007) Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 92(5):583–588CrossRefPubMed Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E (2007) Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 92(5):583–588CrossRefPubMed
16.
Zurück zum Zitat Britton RS, Leicester KL, Bacon BR (2002) Iron toxicity and chelation therapy. Int J Hematol 76(3):219–228CrossRefPubMed Britton RS, Leicester KL, Bacon BR (2002) Iron toxicity and chelation therapy. Int J Hematol 76(3):219–228CrossRefPubMed
18.
Zurück zum Zitat Melchiori L, Gardenghi S, Rivella S (2010) beta-Thalassemia: HiJAKing ineffective erythropoiesis and iron overload. Adv Hematol 2010:938640PubMedPubMedCentral Melchiori L, Gardenghi S, Rivella S (2010) beta-Thalassemia: HiJAKing ineffective erythropoiesis and iron overload. Adv Hematol 2010:938640PubMedPubMedCentral
20.
Zurück zum Zitat Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, Moroney JW, Reed CH, Luban NLC, Wang RH, Eling TE, Childs R, Ganz T, Leitman SF, Fucharoen S, Miller JL (2007) High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 13(9):1096–1101CrossRefPubMed Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, Moroney JW, Reed CH, Luban NLC, Wang RH, Eling TE, Childs R, Ganz T, Leitman SF, Fucharoen S, Miller JL (2007) High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 13(9):1096–1101CrossRefPubMed
21.
Zurück zum Zitat Haghpanah S, Esmaeilzadeh M, Honar N, Hassani F, Dehbozorgian J, Rezaei N, Abdollahi M, Bardestani M, Safaei S, Karimi M (2015) Relationship between serum hepcidin and ferritin levels in patients with thalassemia major and intermedia in southern Iran. Iran Red Crescent Med J 17(7):e28343PubMedPubMedCentral Haghpanah S, Esmaeilzadeh M, Honar N, Hassani F, Dehbozorgian J, Rezaei N, Abdollahi M, Bardestani M, Safaei S, Karimi M (2015) Relationship between serum hepcidin and ferritin levels in patients with thalassemia major and intermedia in southern Iran. Iran Red Crescent Med J 17(7):e28343PubMedPubMedCentral
22.
Zurück zum Zitat Kattamis A, Papassotiriou I, Palaiologou D, Apostolakou F, Galani A, Ladis V, Sakellaropoulos N, Papanikolaou G (2006) The effects of erythropoietic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica. 91(6):809–812PubMed Kattamis A, Papassotiriou I, Palaiologou D, Apostolakou F, Galani A, Ladis V, Sakellaropoulos N, Papanikolaou G (2006) The effects of erythropoietic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica. 91(6):809–812PubMed
Metadaten
Titel
Association between serum levels of hepcidin and ferritin in patients with thalassemia major and intermedia, the role of iron chelator
verfasst von
Seyed Kamal Eshagh Hossaini
Mohammad reza Haeri
Publikationsdatum
11.07.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Hematopathology / Ausgabe 3/2019
Print ISSN: 1868-9256
Elektronische ISSN: 1865-5785
DOI
https://doi.org/10.1007/s12308-019-00363-x

Weitere Artikel der Ausgabe 3/2019

Journal of Hematopathology 3/2019 Zur Ausgabe

Neu im Fachgebiet Pathologie